Company Overview
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
Why Investors Should Care
Net profit has compounded at 14.7% per year over the last five years.
Trades at a P/E of 27.5, below the sector median of 40.0.
Recent Developments
- Mar 2026 Revenue of ₹333.79 Cr (-3.2% YoY); net profit ₹17.31 Cr.
- Trailing 12 Months Year-on-year growth — revenue -3.2%, earnings -13.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.2%, profit CAGR 14.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.22% |
| 1 Year: | -3.17% |
Compounded Profit Growth
| 5 Years: | 14.73% |
| 1 Year: | -13.91% |
Stock Price Performance
| 1 Year: | +33.23% |
| 6 Months: | +18.88% |
| 3 Months: | +21.68% |
| 1 Month: | +10.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.17 · Neutral
P/E of 27.49 is below the sector median of 39.97 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 14.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HALEOSLABS Haleos Labs Limited NSEPHARMA | 1,574.00 | 27.49 | ₹475.87 Cr | 0.09% | 10.61% | 8.11% | 2.22% | 14.73% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 63.73 Cr | 74.65 Cr | 69.26 Cr | 72.05 Cr | 89.99 Cr | 92.55 Cr | 78.46 Cr | 84.60 Cr | 89.11 Cr | 82.50 Cr | 81.37 Cr | 94.78 Cr | 75.14 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 55.65 Cr | 51.64 Cr | 48.34 Cr | 61.14 Cr | 45.96 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 33.47 Cr | 30.86 Cr | 33.03 Cr | 33.64 Cr | 29.18 Cr |
| Operating Expenses | 61.45 Cr | 72.11 Cr | 61.33 Cr | 62.75 Cr | 78.63 Cr | 76.27 Cr | 69.89 Cr | 71.85 Cr | 29.84 Cr | 22.97 Cr | 23.34 Cr | 23.50 Cr | 28.87 Cr |
| Operating Income | -64.00 L | -1.16 Cr | 4.20 Cr | 5.57 Cr | 7.58 Cr | 12.60 Cr | 4.81 Cr | 8.99 Cr | 3.62 Cr | 7.89 Cr | 9.68 Cr | 10.14 Cr | 31.10 L |
| EBITDA | 2.28 Cr | 2.54 Cr | 7.93 Cr | 9.30 Cr | 11.36 Cr | 16.28 Cr | 8.57 Cr | 12.75 Cr | 9.76 Cr | 12.71 Cr | 13.99 Cr | 14.23 Cr | 6.17 Cr |
| Interest Expense | 1.80 Cr | 2.18 Cr | 2.81 Cr | 2.34 Cr | 2.84 Cr | 2.40 Cr | 2.14 Cr | 2.14 Cr | 2.03 Cr | 1.87 Cr | 1.62 Cr | 1.54 Cr | 1.42 Cr |
| Pretax Income | 2.37 Cr | -2.73 Cr | 1.66 Cr | 3.81 Cr | 7.10 Cr | 10.64 Cr | 4.71 Cr | 6.91 Cr | 3.93 Cr | 7.02 Cr | 8.49 Cr | 8.78 Cr | 90.55 L |
| Tax Provision | 25.00 L | -1.10 Cr | 2.10 Cr | -31.01 L | 61.98 L | 3.54 Cr | 1.40 Cr | 2.06 Cr | 44.58 L | 2.64 Cr | 2.07 Cr | 2.13 Cr | 56.16 L |
| Net Income | 2.11 Cr | -3.83 Cr | -44.00 L | 4.12 Cr | 6.47 Cr | 7.10 Cr | 3.30 Cr | 4.86 Cr | 2.97 Cr | 4.16 Cr | 6.10 Cr | 6.62 Cr | 43.57 L |
| Diluted EPS | 5.66 | -5.95 | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.83 | 13.75 | 20.19 | 21.89 | 1.44 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 378.00 Cr | 261.00 Cr | 266.00 Cr | - | 312.55 Cr | 299.56 Cr | 344.72 Cr | 333.79 Cr |
| Cost of Revenue | - | - | - | - | 228.00 Cr | 208.79 Cr | 216.61 Cr | 204.94 Cr |
| Gross Profit | - | - | - | - | 84.55 Cr | 90.77 Cr | 128.11 Cr | 128.86 Cr |
| Operating Expenses | 343.00 Cr | 235.00 Cr | 235.00 Cr | - | 66.50 Cr | 74.48 Cr | 98.07 Cr | 99.65 Cr |
| Operating Income | 29.00 Cr | 17.00 Cr | 22.00 Cr | - | 18.05 Cr | 16.28 Cr | 30.04 Cr | 29.21 Cr |
| EBITDA | 35.00 Cr | 25.00 Cr | 30.00 Cr | - | 33.81 Cr | 34.74 Cr | 49.90 Cr | 47.11 Cr |
| Interest Expense | 6.00 Cr | 5.00 Cr | 5.00 Cr | - | 6.42 Cr | 9.95 Cr | 8.71 Cr | 6.45 Cr |
| Pretax Income | 25.00 Cr | 15.00 Cr | 20.00 Cr | - | 16.59 Cr | 9.85 Cr | 26.19 Cr | 25.20 Cr |
| Tax Provision | 7.50 Cr | 4.65 Cr | 6.20 Cr | - | 5.22 Cr | 3.52 Cr | 7.46 Cr | 7.40 Cr |
| Net Income | 18.00 Cr | 10.00 Cr | 14.00 Cr | - | 11.46 Cr | 9.09 Cr | 20.11 Cr | 17.31 Cr |
| Diluted EPS | 59.04 | 33.67 | 44.85 | - | 37.92 | 30.08 | 66.51 | 57.26 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 270.00 Cr | 253.00 Cr | 302.00 Cr | - | 394.89 Cr | 391.33 Cr | 389.99 Cr | 454.41 Cr |
| Current Assets | - | - | - | - | 159.12 Cr | 156.08 Cr | 150.57 Cr | 163.11 Cr |
| Cash & Equivalents | - | - | - | - | 1.28 Cr | 56.95 L | 50.29 L | 1.21 Cr |
| Inventory | - | - | - | - | 86.23 Cr | 81.21 Cr | 67.40 Cr | 79.82 Cr |
| Receivables | - | - | - | - | 46.06 Cr | 51.35 Cr | 68.79 Cr | 61.34 Cr |
| Total Liabilities | - | - | - | - | 206.67 Cr | 197.69 Cr | 177.94 Cr | 224.85 Cr |
| Current Liabilities | - | - | - | - | 133.56 Cr | 145.37 Cr | 142.07 Cr | 156.28 Cr |
| Long Term Debt | - | - | - | - | 54.94 Cr | 33.15 Cr | 18.27 Cr | 49.96 Cr |
| Total Debt | 47.00 Cr | 65.00 Cr | 65.00 Cr | - | 100.49 Cr | 100.72 Cr | 86.41 Cr | 110.54 Cr |
| Total Equity | 106.00 Cr | 116.00 Cr | 129.00 Cr | - | 168.61 Cr | 176.81 Cr | 196.56 Cr | 213.55 Cr |
| Shares Outstanding | - | - | - | - | 30.23 L | 30.23 L | 30.23 L | 30.23 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 30.00 Cr | 15.00 Cr | 35.00 Cr | - | 14.70 Cr | 24.31 Cr | 34.05 Cr | 37.22 Cr |
| Investing Cash Flow | -44.00 Cr | -27.00 Cr | -26.00 Cr | - | -31.29 Cr | -18.45 Cr | -15.00 Cr | -57.90 Cr |
| Financing Cash Flow | 15.00 Cr | 12.00 Cr | -3.00 Cr | - | 16.89 Cr | -6.56 Cr | -19.12 Cr | 21.38 Cr |
| Capital Expenditure | -24.00 Cr | -24.00 Cr | -35.00 Cr | - | -48.55 Cr | -20.87 Cr | -15.35 Cr | -57.86 Cr |
| Free Cash Flow | 6.00 Cr | -9.00 Cr | -0 | - | -33.86 Cr | 3.44 Cr | 18.71 Cr | -20.64 Cr |
| Net Change in Cash | 1.00 Cr | -0 | 6.00 Cr | - | 29.18 L | -70.84 L | -6.66 L | 70.55 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 27.1% | 30.3% | 37.2% | 38.6% |
| Operating Margin % | 7.7% | 6.5% | 8.3% | - | 5.8% | 5.4% | 8.7% | 8.8% |
| Net Margin % | 4.8% | 3.8% | 5.3% | - | 3.7% | 3.0% | 5.8% | 5.2% |
| ROE % | 17.0% | 8.6% | 10.9% | - | 6.8% | 5.1% | 10.2% | 8.1% |
| ROCE % | - | - | - | - | 6.9% | 6.6% | 12.1% | 9.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HALEOSLABS
HALEOSLABS Stock Price and Chart — NSE:HALEOSLABS - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1JemlfbDJ5Q0lsTEtXcThUbkk5NlotWjFYR2FhcUppY1lubkUyZXI3S2x0OXlXbUxUX1BEU0hoN3JBNVpBYVFKdndEeVpma0RQbWFHTk5QaE5IYk9ONWl6UQ?oc=5" target="_blank">HALEOSLABS Stock Price and Chart — NS…
Is The Market Rewarding Haleos Labs Limited (NSE:HALEOSLABS) With A Negative Sentiment As A Result Of Its Mixed Fundamentals? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPVm95dGNmanBLMFZPY0xnSzRfaEVqVkh2M3BfTkJaQ2NIbjJ3LVVpaThuaGRxb181LURBdVYzeXpFX0EyN0NPRWEzMF9JUTZVR0I4M21xMDRWM0I3dnVEUDJMWTlrTHJvaEExcTVLekcxVkw2TU91M2JDaEJKWkNDQlNJUmdZQUpaS1ZiVH…
Haleos Labs Limited Updates Official Contact Details Following Name Change - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQV2ZWVDBUeTc4T3QxZDQ1RHZKQWs4UE5YYlpMRWMxWDdaTFZtT243dWt6ZTh1R0V4V3Y1Rkx3MjZ2RUlDaVpkQjFIWHBZVDgwYkRDV1JiZ1NOYVhxQkVWTzU5VHJWbjY2WWc5NkJCSjd1N1Q1Y0NFSTg0UUJPeFF6aDBVSkhHSGc3b1dlNH…
SMS Lifesciences India Limited Rebrands as Haleos Labs Limited - scanx.trade
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNN1Y2VmZnNmxNaWF2aF9xREYtdWJFYm84THB5V0p0SFVMVlA2UWtFbXNYUTRjdU01aWNUR3Z6WkRZbTA4Y2FCaDJ3SXdPX0doSDBGSF9XSGJhSG82VjJneEN6cEd1bFRwcXY0N0xqd3hoN0ZoanVTQzdLaXhMU0dBb1FGeEZEZUJocEp1ZX…
Haleos Labs Ltd. Share Price Today - Haleos Labs Ltd. Stock Price Live NSE/BSE - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5LYnJGa0owdmd3cEplYjF6RjNBZDRRYnFSTGhqeVMzMndyLVZpNlVqRTBmcWZtbW5mQXJVUzF2bTdDczMzbl9zOTBVYzdGaXA5SE9jakhaTVBFSkQ3RWlMZjVVSldsV29Ga0lIWW5pdFctRnZsY3BDVm5BNTBadw?oc=5" target="_blan…
FABTECH Stock Price and Chart — NSE:FABTECH - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBJUUhXbU41UGZVWmxfQ2U4X29pOVVHdnpiUVB5U2RvanRVb09ZbTgyNkVSek5QNjhDaVQ0eFZLQnNSQ2FvUTJtcDFSQzdSVDJEajhEMGFraXJFZUdq?oc=5" target="_blank">FABTECH Stock Price and Chart — NSE:FABTECH…
HALEOSLABS — Frequently Asked Questions
What is the current share price of Haleos Labs Limited (HALEOSLABS)?
As of 2026-07-15 09:52 IST, Haleos Labs Limited (HALEOSLABS) trades at ₹1,574.00 on NSE. Its 52-week range is ₹1,077.45 to ₹1,690.10.
What is the market capitalisation of HALEOSLABS?
Haleos Labs Limited (HALEOSLABS) has a market capitalisation of ₹475.87 Cr on NSE.
What is the P/E ratio of HALEOSLABS?
HALEOSLABS trades at a trailing price-to-earnings (P/E) ratio of 27.49. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.25.
Does HALEOSLABS pay a dividend?
Haleos Labs Limited (HALEOSLABS) currently offers a dividend yield of 0.09%.
What is the return on equity (ROE) of HALEOSLABS?
HALEOSLABS has a return on equity (ROE) of 8.11%. Its return on capital employed (ROCE) is 10.61%.
Is HALEOSLABS a good stock to buy?
This page provides a data-driven analysis of Haleos Labs Limited (HALEOSLABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.